A multibillion-dollar decision to launch a vaccine based wholly or in part on the BA.1, BA.4, or BA.5 Omicron sequences need not be rushed. Using an additional week or two to obtain more input seems a prudent step to take.
FDA: Don't Rush to Change Covid Vax Composition
Comment
Show comments
Hide Comments
